Friday, May 18, 2018 · 5:15 a.m. – 7:30 a.m.
5:15 – 5:45 a.m. Breakfast
5:45 a.m. – 7:30 a.m. Educational Session
Constitution Ballroom, Sheraton Boston
Don’t miss this educational program offering cutting-edge continuing education on the profiles of injectable GLP-1 RA therapies for T2D management. Examine their role in individualized care, review the most recent clinical trial data on injectable therapies and CV risk, discuss emerging clinical trial data on renal risk: benefit profiles of these therapies and how to integrate these pharmacotherapies into daily clinical practice. Three case-based, interactive modules will present information on the latest developments in the field of noninsulin injectable therapies in patients with T2D. This symposium includes an “Ask the Experts” session allowing participants to discuss their challenging cases. This real-world education will provide endocrinologists and other clinicians with the information they need to offer the highest-quality medical care for their patients with T2D.
Presentations and Speakers
Program Chair and Moderator: Daniel Einhorn, MD, FACP, FACE
Non-Insulin Injectable Therapies for Diabetes Management: GLP-1 Receptor Agonists: Vivian Fonseca, MD, FRCP, FACE
GLP-1 Receptor Agonists and Cardiovascular Risk: Mikhail Kosiborod, MD, FACC, FAHA
The Albuminuria Effect: GLP-1 RAs, the Kidneys, and Cardiovascular Outcomes Trials: Ralph DeFronzo, MD
This program is supported by an independent educational grant from Novo Nordisk.
Program Management provided by AACE.